Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Kinex Licenses China Rights for Cancer Molecule to Hanmi Pharma

publication date: Apr 21, 2011
Kinex Pharmaceuticals, a privately held pharma in New York State, has out-licensed China rights for its lead molecule, KX01, to Hanmi Pharmaceutical Co. of South Korea. KX01 has completed a Phase I trial for end-stage cancer in the US, where it showed a clinical response in 25% of the patients. Hanmi has rights to KX01 in China and other selected Asian countries for all oncology indications. Financial terms were not disclosed. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital